Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2008
12/04/2008WO2008022974A3 Anti-diabetes composition containing chicoric acid and/or one of the metabolites thereof
12/04/2008WO2008022113A3 Methods for treating rheumatoid arthritis
12/04/2008WO2008022105A3 Compositions and methods for nutrition supplementation
12/04/2008WO2008021788A3 Polyamine compounds
12/04/2008WO2008021149A3 Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
12/04/2008WO2008021076A3 Protein matrix vaccines and methods of making and administering such vaccines
12/04/2008WO2008016887A3 Methods and pharmaceutical compositions to treat gastric acid disorders
12/04/2008WO2008015539A3 Topical preparation containing sirolimus for treating inflammatory skin deseases
12/04/2008WO2008013986A3 Compositions and methods for treating or preventing ophthalmic light toxicity
12/04/2008WO2008013900A3 Osteogenic enhancer composition
12/04/2008WO2008011426A3 Methods and medicaments for administration of ibuprofen
12/04/2008WO2008008517A3 Bridged diazepan orexin receptor antagonists
12/04/2008WO2008005769A3 Methods of inhibiting hcv replication
12/04/2008WO2008005692A3 INHALANT FORMULATION CONTAINING SULFOALKYL ETHER γ-CYCLODEXTRIN AND CORTICOSTEROID
12/04/2008WO2008002849A3 Aryl sulfones
12/04/2008WO2007150016A3 Il-8 receptor antagonist
12/04/2008WO2007146965A3 Compounds for the treatment of periodontal disease
12/04/2008WO2007146122A3 Tetrahydropyrido[3,4-d]pyrimidines and related analogues
12/04/2008WO2007140231A3 Low molecular weight heparin composition and uses thereof
12/04/2008WO2007136940A3 Thiazolidinedione derivatives as pi3 kinase inhibitors
12/04/2008WO2007135505A8 Veterinary pharmaceutical compositions for the treatment of pain and inflammation
12/04/2008WO2007134533A8 20(R)-GINSENOSIDE Rg3 MEDICINAL SOLUBLE INTERMEDIATE AND PROCESS THEREOF
12/04/2008WO2007134279A3 Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
12/04/2008WO2007127207A3 Fixed combination dosage forms for the treatment of migraine
12/04/2008WO2007127198A3 Protein crosslinkers, crosslinking methods and applications thereof
12/04/2008WO2007126473A3 Oligomerization of amyloid proteins
12/04/2008WO2007124452A3 Methods for expressing multiple sirna and shrna from a single vector
12/04/2008WO2007124435A3 Detection of histone deacetylase inhibition
12/04/2008WO2007121347A3 Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
12/04/2008WO2007121272A3 Methods and compositions involving nucleotide repeat disorders
12/04/2008WO2007120160A3 Lactam containing hcv inhibitors
12/04/2008WO2007118065A3 siRNA NANOPROBES
12/04/2008WO2007115306A3 Compounds for diseases and disorders
12/04/2008WO2007115168A3 Compositions and methods for inhibiting expression of eg5 gene
12/04/2008WO2007109105A3 Flavivirus inhibition by sultams and related compounds
12/04/2008WO2007108958A3 Methods of treating cancer using hypofractionated radiation and texaphyrins
12/04/2008WO2007106622A3 Fungicidal formulation and method of use
12/04/2008WO2007098229A3 Geldanamycin derivatives and method of use thereof
12/04/2008WO2007095639A3 Napht alimide compositions and uses thereof
12/04/2008WO2007095536A3 Treatment and prevention of renal disease
12/04/2008WO2007095497A3 Compositions and methods for prevention and treatment of cachexia
12/04/2008WO2007092496A3 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
12/04/2008WO2007092161A3 A direct cellular energy delivery system
12/04/2008WO2007084231A3 Treatment of inflammation and organ dysfunction
12/04/2008WO2007075749A3 Niacin receptor agonists, compositions containing such compounds and methods of treatment
12/04/2008WO2006091936A3 Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
12/04/2008WO2006073973A3 Novel benzylamine derivatives as cetp inhibitors
12/04/2008WO2006029040A3 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
12/04/2008US20080300424 7-substituted fused ring tetracycline compounds
12/04/2008US20080300407 Pyridinoylpiperidines as 5-HT1F agonists
12/04/2008US20080300398 Therapy for hepatitis B virus infection ; antiproliferative agents; antitumor agents; anticancer agents; HIV
12/04/2008US20080300384 T-bet compositions and methods of use thereof
12/04/2008US20080300319 Methods for preventing or inhibiting post-surgical adhesions
12/04/2008US20080300317 Diamondoid derivatives possessing therapeutic activity in the treatment of viral disorders
12/04/2008US20080300316 Substituted phenethylamines
12/04/2008US20080300315 Stabilized Compositions Comprising a Therapeutically Active Agent, and an Oxidizing Preservative
12/04/2008US20080300312 Treatment of cancer with specific RXR agonists
12/04/2008US20080300311 Diclofenac gel
12/04/2008US20080300310 Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
12/04/2008US20080300309 Creatine Hydroxycitric Acids Salts and Methods for their Production and use in Individuals
12/04/2008US20080300308 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
12/04/2008US20080300307 Stable gabapentin compositions
12/04/2008US20080300306 Novel Compounds
12/04/2008US20080300305 Method of purifying pravastatin
12/04/2008US20080300304 Ginger Fraction For Inhibiting Human Cyp Enzymes
12/04/2008US20080300302 Stabilized 3-Hydroxyflavan Compositions and Methods Therefor
12/04/2008US20080300301 Composition for Promoting Production of Hyaluronic Acid Containing Kaempferol and Quercetin
12/04/2008US20080300299 Application of Eriocalyxin B in the Manufacture of Medicaments For Treating Leukemia
12/04/2008US20080300298 Honokiol Derivates For the Treatment of Proliferative Disorders
12/04/2008US20080300297 Taxane derivative containing pharmaceutical composition with improved therapeutic efficacy
12/04/2008US20080300296 Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith
12/04/2008US20080300295 Inhibitors of Ccr9 Activity
12/04/2008US20080300294 Novel Thiophene Derivatives
12/04/2008US20080300293 Combination of an dpp-iv inhibitor and a ppar-alpha compound
12/04/2008US20080300292 Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders
12/04/2008US20080300291 Potent indole-3-carbinol-derived antitumor agents
12/04/2008US20080300290 Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments
12/04/2008US20080300289 (R,S)-5-[1-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-2-methyl-propyl]-thiophene-2-carboxylic acid (2H-tetrazol-5-ylmethyl)-amide, used for the treatment of metabolic disorders, such as diabetes, non-insulin dependent diabetes and hyperglycemia
12/04/2008US20080300288 Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof
12/04/2008US20080300287 Peptidic Compounds
12/04/2008US20080300286 Tyrosine Derivatives Substituted By N-Arylacryloyl as Agonists of Hppar Alpha and/or Hppar Gamma
12/04/2008US20080300284 sustained release niacin formulation with side effect reduction of liver toxicity and effects on glucose metabolism and uric acid levels
12/04/2008US20080300282 Coupling thiazolidine-2,4-dione with p-(2-alkylpyridyl-2-hydroxy-, Cl-, Br-, mesyl- or tosyl-ethoxybenzaldehyde in a solvent, an organic base and an organic acid catalyst and hydrogenating the product to form 5-[4-[2-(alkylpyridyl)2-hydroxy-, Cl-, Br-, mesyl- or tosylethoxy]benzyl-2,4-thiazolidinedione
12/04/2008US20080300281 Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
12/04/2008US20080300279 Piperidine-amide derivatives
12/04/2008US20080300278 central nervous system disorders; respiratory system disorders; sexual or reproductive disorders; gastrointestinal disorders; eating disorders; antidiabetic agents; anticancer agents; cardiovascular disorders
12/04/2008US20080300277 Process to improve stability of a pharmaceutical composition
12/04/2008US20080300276 Heterocyclic Carboxylic Acide Amide Derivatives
12/04/2008US20080300275 Novel Benzothiazolone Derivatives
12/04/2008US20080300274 Novel Pyrrolidino-1,4-Naphthoquinone Deriviatives and their Use for Treating Malignancies and Cardiovascular Diseases
12/04/2008US20080300273 Method of Treating Abnormal Cell Growth
12/04/2008US20080300272 Injectable dosage form of aqueous solution including a buffer and optional amino acid at alkaline pH; e.g. argatroban, lactobionic acid, and methionine; free of ethanol, saccharides and sugar alcohols; reducing dosage errors, storage stability
12/04/2008US20080300271 Novel compounds and a novel process for their preparation
12/04/2008US20080300270 4-Phenyl-5-Oxo-1,4,5,6,7,8,- Hexahydroquinoline Derivatives as Medicaments for the Treatment of Infertility
12/04/2008US20080300269 Glaucoma; prostaglandin receptor modulators; cyclopentyl compounds such as 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid
12/04/2008US20080300268 Heterocyclic compounds and uses thereof
12/04/2008US20080300267 (3-Chloro-phenyl)-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-pyrimidin-2-yl]-amine; (4-Fluoro-phenyl)-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-pyrimidin-2-yl]-amine; [4-(1H-Pyrrolo[2,3-b]pyridin-4-yl)-pyrimidin-2-yl]-(4-trifluoromethoxy-phenyl)-amine;
12/04/2008US20080300266 metabotropic glutamate receptor (mGluR3) antagonists such as [1-(5-bromopyrimidin-2-yl)-pyrrolidin-3-yl]-(2,4-dichlorobenzyl)-amine, used for the treatment of depression, schizophrenia and headaches
12/04/2008US20080300265 Antiviral drugs for treatment of arenavrus infection
12/04/2008US20080300264 Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
1 ... 2965 2966 2967 2968 2969 2970 2971 2972 2973 2974 2975 2976 2977 2978 2979 2980 2981 2982 2983 2984 2985 ... 7860